Company profile for Hyundai Bioscience

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

HYUNDAI BIOSCIENCE’s research & innovation center has continuously produced globally recognized research results with the commercialization of LDH based on Organic-Inorganic Hybrid technology. Based on the long accumulated research know-how, HYUNDAI BIOSCIENCE is the only company commercialized new DDS (Drug Delivery System) using LDH Platform Technology. Through application of LDH Platform Technology, our research & innova...
HYUNDAI BIOSCIENCE’s research & innovation center has continuously produced globally recognized research results with the commercialization of LDH based on Organic-Inorganic Hybrid technology. Based on the long accumulated research know-how, HYUNDAI BIOSCIENCE is the only company commercialized new DDS (Drug Delivery System) using LDH Platform Technology. Through application of LDH Platform Technology, our research & innovation center has developed a variety of DDS commercialization techniques such as oral, dermal and injection. We hold various patents for these techniques and materials both domestically and internationally.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
3rd floor Academic Cooperation Building Ehwa Women’s University 150 North-Ah...
Telephone
Telephone
+82 70 7008 0114
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/penetrium-breaks-oncology-barriers-the-solution-to-cold-tumors-and-metastatic-cancer-unveiled-at-aacr-2025-302449437.html

PR NEWSWIRE
07 May 2025

https://www.biospectrumasia.com/news/25/25539/hyundai-bio-and-dndi-sign-mou-for-joint-development-of-xafty-based-dengue-treatment.html

BIOSPECTRUM
06 Feb 2025

https://www.prnewswire.com/news-releases/hyundai-bioscience-to-conduct-phase-3-clinical-trial-for-high-risk-group-of-covid-19-patients-with-the-goal-of-emergency-use-authorization-302232773.html

PR NEWSWIRE
28 Aug 2024

https://www.prnewswire.com/news-releases/adm-korea-announces-niclosamide-based-metabolic-anticancer-drugs-first-clinical-trial-target-as-prostate-cancer-patients-resistant-to-hormone-therapy-302194534.html

PR NEWSWIRE
11 Jul 2024

https://www.prnewswire.com/news-releases/hyundai-bioscience-succeeds-in-developing-multi-treatment-for-mosquito-borne-viral-infections-including-dengue-fever-302182515.html

PR NEWSWIRE
25 Jun 2024

https://www.biospectrumasia.com/news/25/24109/korean-firm-hyundai-bioscience-soon-to-initiate-global-clinical-development-on-dengue-antiviral-candidate.html

BIOSPECTRUM ASIA
22 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty